ArticleMolecular therapy oncolytics2019
Assessing the Completeness of Reporting in Preclinical Oncolytic Virus Therapy Studies.
Article in Molecular therapy oncolytics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 5 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- Preclinical systematic review of CCR5 antagonists as cerebroprotective and stroke recovery enhancing agents.eLife · 2025Pooled it
- Pooled it
- Mesenchymal stromal cell extracellular vesicles as therapy for acute and chronic respiratory diseases: A meta-analysis.Journal of extracellular vesicles · 2021Pooled it
- Neuroprotection by Remote Ischemic Conditioning in Rodent Models of Focal Ischemia: a Systematic Review and Meta-Analysis.Translational stroke research · 2021Pooled it
- Pooled it
- Emerging role of mesenchymal stromal cells in gynecologic cancer therapy.Stem cell research & therapy · 2023Review
- Identifying barriers and enablers to rigorous conduct and reporting of preclinical laboratory studies.PLoS biology · 2023Article
- Construction of a Myc-associated ceRNA network reveals a prognostic signature in hepatocellular carcinoma.Molecular therapy. Nucleic acids · 2021Article
- MicroRNA-497-5p Is Downregulated in Hepatocellular Carcinoma and Associated with Tumorigenesis and Poor Prognosis in Patients.International journal of genomics · 2021Article
- Long Noncoding RNA OIP5-AS1 Promotes the Progression of Liver Hepatocellular Carcinoma via Regulating the hsa-miR-26a-3p/EPHA2 Axis.Molecular therapy. Nucleic acids · 2020Article
- Photoactivatable oncolytic adenovirus for optogenetic cancer therapy.Cell death & disease · 2020Article
- Identifying and understanding factors that affect the translation of therapies from the laboratory to patients: a study protocol.F1000Research · 2020Article
- Power and Promise of Next-Generation Sequencing in Liquid Biopsies and Cancer Control.Cancer control : journal of the Moffitt Cancer CenterReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Irreproducibility of preclinical findings could be a significant barrier to the "bench-to-bedside" development of oncolytic viruses (OVs). A contributing factor is the incomplete and non-transparent reporting of study methodology and design. Using the NIH Principles and Guidelines for Reporting Preclinical Research, a core set of seven recommendations, we evaluated the completeness of reporting of preclinical OV studies. We also developed an evidence map identifying the current trends in OV research. A systematic search of MEDLINE and Embase identified all relevant articles published over an 18 month period. We screened 1,554 articles, and 236 met our
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.